Genprex Announces Enrollment of First Patient in Phase 2 Expansion Study
Acclaim-3 Study Progresses Towards Interim Analysis
AUSTIN, Texas , Jan. 23, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Phase 2 expansion portion of the Company’s Acclaim-3 clinical study of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC).
“We are excited to begin the Phase 2 expansion portion of Acclaim-3, which will determine the 18-week Progression Free Survival (PFS) rate of REQORSA and Tecentriq combination maintenance therapy,” said Mark Berger, MD, Chief Medical Officer at Genprex.
Genprex expects to complete enrollment of the first 25 patients in the Phase 2 expansion study during the second half of 2025 for interim analysis. The Acclaim-3 Study has FDA Orphan Drug and Fast Track designations, highlighting the significance of this research in the field of cancer therapy.
This new phase of the study marks a crucial step towards assessing the efficacy and safety of the combination therapy in treating ES-SCLC patients, offering new hope for those battling this aggressive form of lung cancer.
Impact on Patients:
For patients diagnosed with ES-SCLC, the results of the Acclaim-3 study could potentially provide a groundbreaking treatment option that improves survival rates and quality of life. The combination of Reqorsa® Gene Therapy and Tecentriq® as maintenance therapy offers a promising approach to managing this difficult-to-treat cancer.
Impact on the World:
Advancements in cancer therapy, such as the developments made in the Acclaim-3 study, have the potential to revolutionize the way we treat various forms of cancer. The innovative approach taken by Genprex may pave the way for more effective and targeted treatments in the future, impacting not only patients with ES-SCLC but also those with other types of cancer.
Conclusion:
The enrollment of the first patient in the Phase 2 expansion study of the Acclaim-3 trial represents a significant milestone in the development of novel cancer therapies. Genprex’s dedication to advancing gene therapy for the treatment of ES-SCLC shows promise for improving patient outcomes and shaping the future of cancer treatment.
